Profile: Mylan Inc (MYL.OQ)
33.99USD
4:00pm EDT
$0.43 (+1.28%)
$33.56
$33.73
$34.62
$33.54
1,261,976
1,207,039
$34.62
$22.51
Mylan Inc. (Mylan), incorporated on August 31, 1970, is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. The Company's pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan provides products to customers in approximately 140 countries and territories.
The Company maintains one of the industry’s broadest and product portfolios, supported by a robust product pipeline and one of the vertically integrated active pharmaceutical ingredient (API) operations. Additionally, it operates a specialty business which is focused on respiratory, allergy and psychiatric therapies. Mylan markets a global portfolio of approximately 1,100 different products covering an array of therapeutic categories. The Company offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, the Company focuses on those that are difficult to formulate and manufacture and typically have longer product life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. Mylan also manufactures and supplies low cost, API for its own products and pipeline, as well as for third parties.
Generics Segment
Mylan holds the number two ranking in the U.S. generics prescription market in terms of both sales and prescriptions dispensed. One in every 11 prescriptions dispensed in the United States is a Mylan product. The Company's sales in the United States are derived principally through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through its wholly owned subsidiary Mylan Institutional (MI). MPI’s net revenues are derived primarily from the sale of solid oral dosage and transdermal patch products. In the United States, the Company consists of approximately 365 products, of which approximately 310 are in capsule or tablet form in an aggregate of approximately 880 dosage strengths. Included in these totals are approximately 40 extended-release products in a total of approximately 105 dosage strengths. Also included in its United States product portfolio are three transdermal patch products in a total of 15 dosage strengths that are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
Mylan Institutional focuses on providing a differentiated product offering tailored to institutional customers throughout North America, including group purchasing organizations, wholesalers, hospitals, surgical services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies and retail outlets. MI has, among other product offerings, a diverse portfolio of approximately 40 injectable products (branded and generic) in a total of approximately 60 dosage strengths, across several therapeutic areas for the hospital setting, including analgesics/anesthetics, anti-infections, cardiology and oncology. In addition to the products it manufactures in the United States, it also markets approximately 50 generic products in a total of approximately 75 dosage strengths under supply and distribution agreements with wholesalers. The Company’s North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 120 products in an aggregate of approximately 300 dosage strengths.
The Company’s generic pharmaceutical sales in EMEA are generated primarily by the Company’s wholly owned subsidiaries in Europe, through which it has operations in 21 countries. MPC offers a portfolio of approximately 120 products in an aggregate of approximately 300 dosage strengths. In France, through its subsidiary Mylan S.A.S., the Company markets a portfolio of approximately 305 products in an aggregate of approximately 645 dosage strengths. In Italy, the Company markets through its subsidiary Mylan S.p.A. a portfolio of approximately 175 products in an aggregate of approximately 345 dosage strengths. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 110 products in an aggregate of approximately 300 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 160 products in an aggregate of approximately 360 dosage strengths. In the United Kingdom, it offers a broad product portfolio of approximately 190 products in an aggregate of approximately 405 dosage strengths.
The Company operates in several other European markets, including the Netherlands, Sweden, Poland, Hungary, Slovakia, Slovenia and the Czech Republic. Additionally, it has an export business which is focused on Africa and the Middle East. The Company markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, Japan, New Zealand, India and Taiwan. Additionally, through Mylan India, it markets API to third parties and supply other Mylan subsidiaries.
Mylan India manufactures and supplies low cost, high quality API for its own products and pipeline, as well as for third parties. Mylan India manufacturers as measured by the number of drug master files (DMFs) filed with regulatory agencies and is among the leaders in supplying API for the manufacturing of antiretroviral (ARV) drugs, which are utilized in the treatment of Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome (HIV/AIDS). Mylan India also produces a line of finished dosage form (FDF) products in the ARV market, which are sold mostly outside of India. Additionally, Mylan India manufactures non-ARV FDF products that are marketed and sold to third parties by other Mylan operations around the world.
Through the Company’s wholly owned subsidiary Alphapharm, it offers a portfolio of approximately 180 products in an aggregate of approximately 375 dosage strengths. The Australian generics market is still underdeveloped and, as a result, the government is increasingly focused on encouraging the use of generics in an effort to reduce costs. Mylan Seiyaku Ltd. (Mylan Seiyaku), its wholly owned Japanese subsidiary, offers a broad portfolio of more than 360 products in an aggregate of approximately 500 dosage strengths.
Specialty Segment
The Company’s specialty pharmaceutical business is conducted through Mylan Specialty, which competes primarily in the respiratory, severe allergy and psychiatry markets. Mylan Specialty’s portfolio consists of primarily branded specialty injectable, nebulized and transdermal products for life-threatening conditions. A portion of Mylan Specialty’s revenues are derived through the sale of the EPIPEN Auto-Injector.
Mylan Specialty has worldwide rights to the epinephrine auto-injector, which is supplied to Mylan Specialty by a wholly owned subsidiary of Pfizer. Anaphylaxis is a severe allergic reaction that is rapid in onset and may cause death, either through swelling that shuts off airways or through drop in blood pressure. Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for long-term, twice-daily administration in the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients, including those with chronic bronchitis and emphysema.
Company Address
Mylan Inc
1500 Corporate Drive
CANONSBURG PA 15317
P: +1724.5141800
F: +1724.5141870
Company Web Links
| Name | Compensation |
|---|---|
Robert Coury |
28,032,800 |
Rajiv Malik |
9,746,890 |
Heather Bresch |
9,960,240 |
Rodney Piatt |
-- |
John Sheehan |
4,278,230 |
- Mylan earnings rise, but dollar drags on revenue
- UPDATE 2-Mylan earnings rise, but dollar drags on revenue
- Mylan second quarter earnings rise, but foreign exchange drags
- Mylan says court dismisses some of Teva's patent claims on MS drug
- Mylan says court dismisses some of Teva's patent claims on MS drug

